Last reviewed · How we verify
Ezetimibe or ezetimibe-statin combination therapy
At a glance
| Generic name | Ezetimibe or ezetimibe-statin combination therapy |
|---|---|
| Sponsor | Sin Gon Kim |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Urinary tract infection
- Hypertension
- Diarrhoea
- Upper respiratory tract infection
- COVID-19
- Back pain
- Fatigue
- Constipation
- Nasopharyngitis
- Arthralgia
- Headache
- Bronchitis
Key clinical trials
- A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events (PHASE3)
- Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study) (NA)
- Early Statin-Ezetimibe Combination vs. Statin Monotherapy in Stroke With Atherosclerosis (PHASE2)
- The Precision CAD Trial (NA)
- Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial (NA)
- Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies (PHASE3)
- Efficacy of Probucol Combined with Statins Treatment for Ischemic Stroke
- Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: